Novo Nordisk's Triple-Thrust Strategy to Revive a Slumping Stock

Novo Nordisk launches Wegovy HD injection and oral pill to combat Eli Lilly, gains EU storage advantage, and executes buybacks amid a tough 2026 sales forecast.

Novo Nordisk shares have shed roughly 28% of their value since the start of the year, a stark reflection of investor concerns over intensifying competition and a sobering financial outlook. The Danish pharmaceutical giant is now launching a multi-pronged offensive across product development, pricing, and logistics in a bid to stabilize its equity and defend its leadership in the lucrative GLP-1 market.

Central to this effort is the aggressive expansion of its obesity treatment portfolio. In the United States, the company introduced a new highest-dose version of its Wegovy injection, a 7.2 mg formulation branded as Wegovy HD, on April 7. Priced at approximately $399 per month for self-pay patients, this move is a deliberate strategy to attract price-sensitive consumers and compete directly with Eli Lilly's Zepbound. Clinical data for this dose showed an average weight reduction of about 21% after 72 weeks.

Simultaneously, the oral version of Wegovy, launched in January, is showing promising early traction. Over 600,000 prescriptions have been written for the pill, which appears to be drawing in new patient groups, particularly those with needle aversion, rather than cannibalizing existing injectable users. Fresh data from the ORION study provides a clinical boost, indicating that Novo Nordisk's oral semaglutid outperforms Eli Lilly's rival drug Orforglipron (marketed as Foundayo) in both weight loss efficacy and tolerability.

Across the Atlantic, the company secured a significant logistical advantage. On April 9, the European Medicines Agency (EMA) approved an extension to Wegovy's label, permitting the injection to be stored at temperatures up to 30 degrees Celsius for up to 48 hours during patient transport. This flexibility eases the strict cold-chain requirements, reduces packaging complexity for pharmacies and online partners, and could help alleviate supply bottlenecks in the EU. Novo Nordisk is the first GLP-1 provider in Europe to gain this edge.

These product advancements unfold against a challenging financial backdrop. Management forecasts a currency-adjusted sales decline between 5% and 13% for the full year 2026. To support the share price during this downturn, the company is actively executing a share buyback program authorized for up to 15 billion Danish kroner. By early April, nearly 10 million shares had been repurchased.

The immediate test for this three-front strategy arrives in May with the release of Novo Nordisk's first-quarter results. This report will deliver the first concrete sales figures for the Wegovy pill and early indicators for the HD injection's launch, offering a clear signal on whether these new products can begin to offset the projected revenue slide.